103 related articles for article (PubMed ID: 26727275)
1. The COL1A1 SP1 polymorphism is associated with lower bone mineral density in patients treated with valproic acid.
Villegas-Martínez I; de-Miguel-Elízaga I; Carrasco-Torres R; Marras C; Canteras-Jordana M; Yedra-Guzmán MJ; Martínez-Villanueva M; Tortosa-Conesa D; Martín-Fernández J
Pharmacogenet Genomics; 2016 Mar; 26(3):126-32. PubMed ID: 26727275
[TBL] [Abstract][Full Text] [Related]
2. Combined effects of collagen type I alpha1 (COL1A1) Sp1 polymorphism and osteoporosis risk factors on bone mineral density in Turkish postmenopausal women.
Kurt-Sirin O; Yilmaz-Aydogan H; Uyar M; Seyhan MF; Isbir T; Can A
Gene; 2014 May; 540(2):226-31. PubMed ID: 24566004
[TBL] [Abstract][Full Text] [Related]
3. COL1A1 Sp1 polymorphism predicts perimenopausal and early postmenopausal spinal bone loss.
MacDonald HM; McGuigan FA; New SA; Campbell MK; Golden MH; Ralston SH; Reid DM
J Bone Miner Res; 2001 Sep; 16(9):1634-41. PubMed ID: 11547832
[TBL] [Abstract][Full Text] [Related]
4. BsmI vitamin D receptor's polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy.
Lambrinoudaki I; Kaparos G; Armeni E; Alexandrou A; Damaskos C; Logothetis E; Creatsa M; Antoniou A; Kouskouni E; Triantafyllou N
Eur J Neurol; 2011 Jan; 18(1):93-8. PubMed ID: 20500803
[TBL] [Abstract][Full Text] [Related]
5. Effects of hormone replacement therapy on bone mineral density in Turkish patients with or without COL1A1 Sp1 binding site polymorphism.
Simsek M; Cetin Z; Bilgen T; Taskin O; Luleci G; Keser I
J Obstet Gynaecol Res; 2008 Feb; 34(1):73-7. PubMed ID: 18226133
[TBL] [Abstract][Full Text] [Related]
6. Association of the type I collagen alpha1 Sp1 polymorphism, bone density and upper limb muscle strength in community-dwelling elderly men.
Van Pottelbergh I; Goemaere S; Nuytinck L; De Paepe A; Kaufman JM
Osteoporos Int; 2001; 12(10):895-901. PubMed ID: 11716195
[TBL] [Abstract][Full Text] [Related]
7. The association between BsmI polymorphism and bone mineral density in young patients with epilepsy who are taking phenytoin.
Phabphal K; Geater A; Limapichart K; Sathirapanya P; Setthawatcharawanich S; Witeerungrot N; Thammakumpee N; Leelawattana R
Epilepsia; 2013 Feb; 54(2):249-55. PubMed ID: 23281616
[TBL] [Abstract][Full Text] [Related]
8. The effect of valproate on bone mineral density in adult epileptic patients.
Boluk A; Guzelipek M; Savli H; Temel I; Ozişik HI; Kaygusuz A
Pharmacol Res; 2004 Jul; 50(1):93-7. PubMed ID: 15082034
[TBL] [Abstract][Full Text] [Related]
9. Bone health and vitamin D status in young epilepsy patients on valproate monotherapy.
Albaghdadi O; Alhalabi MS; Alourfi Z; Youssef LA
Clin Neurol Neurosurg; 2016 Jul; 146():52-6. PubMed ID: 27150607
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of COL1A1 Sp1 polymorphism in relation to bone mineral density and osteoporotic fracture.
Mann V; Ralston SH
Bone; 2003 Jun; 32(6):711-7. PubMed ID: 12810179
[TBL] [Abstract][Full Text] [Related]
11. Genetic control of bone density and turnover: role of the collagen 1alpha1, estrogen receptor, and vitamin D receptor genes.
Brown MA; Haughton MA; Grant SF; Gunnell AS; Henderson NK; Eisman JA
J Bone Miner Res; 2001 Apr; 16(4):758-64. PubMed ID: 11316004
[TBL] [Abstract][Full Text] [Related]
12. Association of the collagen type 1 (COL1A 1) Sp1 binding site polymorphism to femoral neck bone mineral density and wrist fracture in 1044 elderly Swedish women.
Gerdhem P; Brändström H; Stiger F; Obrant K; Melhus H; Ljunggren O; Kindmark A; Akesson K
Calcif Tissue Int; 2004 Mar; 74(3):264-9. PubMed ID: 14595528
[TBL] [Abstract][Full Text] [Related]
13. Bone density and antiepileptic drugs: a case-controlled study.
Stephen LJ; McLellan AR; Harrison JH; Shapiro D; Dominiczak MH; Sills GJ; Brodie MJ
Seizure; 1999 Sep; 8(6):339-42. PubMed ID: 10512774
[TBL] [Abstract][Full Text] [Related]
14. [Decreased bone mineral density and gene polymorphism in primary biliary cirrhosis].
Lakatos PL; Bajnok E; Tornai I; Folhoffer A; Horváth A; Lakatos P; Szalay F
Orv Hetil; 2004 Feb; 145(7):331-6. PubMed ID: 15049048
[TBL] [Abstract][Full Text] [Related]
15. COLIA1 Sp1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy.
Qureshi AM; Herd RJ; Blake GM; Fogelman I; Ralston SH
Calcif Tissue Int; 2002 Mar; 70(3):158-63. PubMed ID: 11907712
[TBL] [Abstract][Full Text] [Related]
16. Bone mineral metabolism changes in epileptic children receiving valproic acid.
Oner N; Kaya M; Karasalihoğlu S; Karaca H; Celtik C; Tütüncüler F
J Paediatr Child Health; 2004 Aug; 40(8):470-3. PubMed ID: 15265190
[TBL] [Abstract][Full Text] [Related]
17. An SP1-binding site polymorphism in the COLIAI gene and osteoporosis in Egyptian patients with thalassemia major.
Hamed HM; Galal A; Ghamrawy ME; Abd El Azeem K; Hussein IR; Abd-Elgawad MF
Blood Coagul Fibrinolysis; 2011 Mar; 22(2):81-5. PubMed ID: 21178584
[TBL] [Abstract][Full Text] [Related]
18. Effect of carbamazepine and valproate on bone mineral density.
Ecevit C; Aydoğan A; Kavakli T; Altinöz S
Pediatr Neurol; 2004 Oct; 31(4):279-82. PubMed ID: 15464641
[TBL] [Abstract][Full Text] [Related]
19. Influence of IL-6, COL1A1, and VDR gene polymorphisms on bone mineral density in Crohn's disease.
Todhunter CE; Sutherland-Craggs A; Bartram SA; Donaldson PT; Daly AK; Francis RM; Mansfield JC; Thompson NP
Gut; 2005 Nov; 54(11):1579-84. PubMed ID: 16009674
[TBL] [Abstract][Full Text] [Related]
20. Determinants of bone mineral density in stable kidney transplant recipients.
Gupta AK; Huang M; Prasad GV
J Nephrol; 2012; 25(3):373-83. PubMed ID: 21928224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
